SCHEMBL22733803

SCHEMBL22733803

CCn1ccnc1C(=O)C=Cc1ccc(CC(=O)Nc2ccc(F)cc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ GFER P55789 1/20 0.46
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ THRB P10828 1/20 0.45
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ ATM Q13315 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ CA12 O43570 1/20 0.42
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ ANO1 Q5XXA6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20754516 1.00 GAA (0.50) GAASMN1; SMN2GFERRAB9AKMT2A
SCHEMBL20746235 0.88 GAA (0.52) GAASMN1; SMN2GFERRAB9AKMT2A
SCHEMBL20746236 0.88 GAA (0.52) GAASMN1; SMN2GFERRAB9AKMT2A
SCHEMBL20754505 0.79 LDHA (0.51) KMT2AMAPTLMNANPSR1ANO1
SCHEMBL22733793 0.79 LDHA (0.51) KMT2AMAPTLMNANPSR1ANO1
SCHEMBL20746571 0.78 NPC1 (0.50) SMN1; SMN2RAB9AKMT2AMEN1MAPK1
SCHEMBL20746570 0.78 NPC1 (0.50) SMN1; SMN2RAB9AKMT2AMEN1MAPK1
SCHEMBL20746446 0.77 KMT2A (0.53) SMN1; SMN2RAB9AKMT2AMEN1MAPK1
SCHEMBL20746448 0.77 KMT2A (0.53) SMN1; SMN2RAB9AKMT2AMEN1MAPK1
SCHEMBL20746553 0.76 GAA (0.53) GAASMN1; SMN2KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200385374-A1 IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME THE UNIVERSITY OF TOLEDO (US) 2020-12-10 — — US claimed
US-20200385374-A1 IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME THE UNIVERSITY OF TOLEDO (US) 2020-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200385374-A1 IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME HDAC1, HDAC8, HDAC2 GAA 846/4885SMN1; SMN2 3892/4885GFER 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback